Metrika

  • citati u SCIndeksu: 0
  • citati u CrossRef-u:0
  • citati u Google Scholaru:[]
  • posete u poslednjih 30 dana:7
  • preuzimanja u poslednjih 30 dana:2

Sadržaj

članak: 3 od 10  
Back povratak na rezultate
2020, vol. 37, br. 2, str. 131-138
"Off-label" primena lekova u dermatologiji - izazovi novih puteva primene određenih starih lekova
Univerzitet u Nišu, Medicinski fakultet, Katedra Farmacija

e-adresamarijatk@medfak.ni.ac.rs
Projekat:
This research was supported by the Faculty of Medicine University of Niš Internal Scientific Project titled: "Investigation of selected synthetic and herbal medicinal substances for off-label skin application."

Ključne reči: "off-label" primena lekova; dermatologija; magistralni lekovi; nosači za lekove
Sažetak
"Off-label" upotreba lekova, tj. upotreba lekova bez dozvole, podrazumeva propisivanje lekova, u smislu doze, indikacija, farmaceutskog oblika i puta primene ili ciljne grupe bolesnika, za koje ne postoji zvanično odobrenje. U poslednje vreme ističu se nove indikacije za određene lekove. "Off-label" upotreba lekova češća je u dermatologiji u odnosu na druge specijalnosti. Ti lekovi uglavnom su dostupni u obliku magistralno izrađenih preparata za lokalnu upotrebu na koži; u tom slučaju obično se ne poklanja dovoljno pažnje izboru nosača i bezbednosti lokalno primenjenog leka, koji je inače indikovan za sistemsku primenu. Štaviše, podloge (baze) koje se tradicionalno koriste kao nosači za magistralno izrađene lekove obično su stabilizovane surfaktantima koji mogu da iritiraju kožu. To svakako nije povoljno imajući u vidu da se stanje inflamatornih dermatoza može pogoršati kada se iste izlažu iritansima. U ovom radu dat je prikaz nekoliko starijih sistemskih lekova, koji se u poslednje vreme upotrebljavaju u lokalnom tretmanu čestih dermatoloških oboljenja i to van zvanično odobrene indikacije. Izbor lekova napravljen je na osnovu informacija o najčešćim magistralnim preparatima ovog tipa, izrađenih prema receptu lekara u apotekama. Cilj rada bio je i prikaz dostupnih naučnih informacija koje se tiču dva, po našem mišljenju, najveća nedostatka "off-label" lokalne upotrebe lekova u dermatologiji: bezbednosti primene finalnih formulacija na kožu i izbora nosača za određene lekove, u smislu njihove stabilnosti i bezbednosti primene.
Reference
Barany, E., Lindberg, M., Loden, M. (2000) Unexpected skin barrier influence from nonionic emulsifiers. Int J Pharm, 195(1-2): 189-95, https://www.sciencedirect.com/science/article/pii/S0378517399003889?via%3Dihub
Bárány, E. (2000) Dry skin and moisturizers. Boca Raton: CRC Press LLC, 243-250, https://www.crcpress.com/Dry-Skin-and-Moisturizers-Chemistry-and-Function/LodenMaibach/p/book/9780849321344
Baselga, E., Roe, E., Coulie, J., Muñoz, F.Z., Boon, L.M., Mccuaig, C., Hernandez-Martín, A., Gich, I., Puig, L. (2016) Risk factors for degree and type of sequelae after involution of untreated hemangiomas of infancy. JAMA Dermatology, 152(11): 1239-1243
Bonifazi, E., Milano, A., Colonna, V. (2013) Evaluation of safety and efficacy of a galenic preparation of 1% propranolol in 89 cases of cutaneous infantile hemangioma. Eur J Pediat Dermatol, 23: 93-104, https://www.ejpd.com/journal/index.php/EJPD/article/view/922
Callender, V., Alexis, A., Stein, G.L., et al. (2018) Long-term topical oxymetazoline hydrochloride 1.0% demonstrates sustained and increasing effect in persistent facial erythema of rosacea. Journal of the American Academy of Dermatology, 79 (3), Supplement 1: AB182, https://www.jaad.org/issue/S0190-9622(18)X0002-4
Chiu, H., Tsai, T. (2011) Topical use of systemic drugs in dermatology: A comprehensive review. Journal of the American Academy of Dermatology, 65(5): 1048.e1-1048.e22, https://www.jaad.org/article/S0190-9622(10)01052-2/abstract
Corazza, M., Strumia, R., Lombardi, A.R., Virgili, A. (1996) Allergic contact dermatitis from spironolactone. Contact Dermatitis, 35(6): 365-366, https://onlinelibrary.wiley.com/doi/abs/10.1111/j.1600-0536.1996.tb02421.x
Draelos, Z.D., Gold, M.H., Weiss, R.A., Baumann, L., Grekin, S.K., Robinson, D.M., Kempers, S.E., Alvandi, N., Weng, E., Berk, D.R., Ahluwalia, G. (2018) Efficacy and safety of oxymetazoline cream 1.0% for treatment of persistent facial erythema associated with rosacea: Findings from the 52-week open label REVEAL trial. Journal of the American Academy of Dermatology, 78(6): 1156-1163, https://www.sciencedirect.com/science/article/pii/S0190962218301464
França, K., Litewka, S. (2019) Controversies in off-label prescriptions in dermatology: The perspective of the patient, the physician, and the pharmaceutical companies. International Journal of Dermatology, 58(7): 788-794, https://onlinelibrary.wiley.com/doi/10.1111/ijd.14222
Hoeger, P.H., Harper, J.I., Baselga, E., Bonnet, D., Boon, L.M., Degli, A.M.C., El, H.M., Oranje, A.P., Rubin, A.T., Weibel, L., Léauté-Labrèze, C. (2015) Treatment of infantile haemangiomas: Recommendations of a European expert group. European Journal of Pediatrics, 174(7): 855-865, https://link.springer.com/article/10.1007%2Fs00431-015-2570-0
Ilić, D., Cvetković, M., Blažević-Kamenov, N., Tasić-Kostov, M. (2019) Topical spironolactone in a natural non-ionic emulsifier based vehicle: A safety assessment. u: Skin and Formulation: 5th Symposium & 17th Skin Forum, Book of abstracts, pp. 57
Jakšić, I., Lukić, M., Malenović, A., Reichl, S., Hoffmann, C., Müller-Goymann, C., Daniels, R., Savić, S. (2012) Compounding of a topical drug with prospective natural surfactant-stabilized pharmaceutical bases: Physicochemical and in vitro/in vivo characterization: A ketoprofen case study. European Journal of Pharmaceutics and Biopharmaceutics, 80(1): 164-175, https://www.sciencedirect.com/science/article/pii/S0939641111002463?via%3Dihub
Ji, Y., Chen, S., Xu, C., Li, L., Xiang, B. (2015) The use of propranolol in the treatment of infantile haemangiomas: An update on potential mechanisms of action. British Journal of Dermatology, 172(1): 24-32, https://onlinelibrary.wiley.com/doi/abs/10.1111/bjd.13388
Kapoor, R., Phiske, M.M., Jerajani, H.R. (2009) Evaluation of safety and efficacy of topical prostaglandin E2 in treatment of vitiligo. British Journal of Dermatology, 160(4): 861-863, https://onlinelibrary.wiley.com/doi/abs/10.1111/j.1365-2133.2008.08923.x
Kelidari, H.R., Saeedi, M., Akbari, J., Morteza-Semnani, K., Gill, P., Valizadeh, H., Nokhodchi, A. (2015) Formulation optimization and in vitro skin penetration of spironolactone loaded solid lipid nanoparticles. Colloids and Surfaces B: Biointerfaces, 128: 473-479, https://www.ncbi.nlm.nih.gov/pubmed/25797482
Kohler, C., Tschumi, K., Bodmer, C., et al. (2007) Effect of finasteride 5 mg (Proscar) on acne and alopecia in female patients with normal serum levels of free testosterone. Gynecol Endocrinol, 23: 142-45, https://www.tandfonline.com/doi/abs/10.1080/09513590701214463?journalCode=igye20
Kunzi-Rapp, K. (2012) Topical propranolol therapy for infantile hemangiomas. Pediatric Dermatology, 29(2): 154-159, Epub ahead of print, https://onlinelibrary.wiley.com/doi/abs/10.1111/j.1525-1470.2011.01615.x
Marqueling, A.L., Oza, V., Frieden, I.J., Puttgen, K.B. (2013) Propranolol and infantile hemangiomas four years later: A systematic review. Pediatric Dermatology, 30(2): 182-191, https://onlinelibrary.wiley.com/doi/abs/10.1111/pde.12089
Mashiah, J., Kutz, A., Rabia, S.H., Ilan, E.B., Goldberg, I., Sprecher, E., Harel, A. (2017) Assessment of the effectiveness of topical propranolol 4% gel for infantile hemangiomas. International Journal of Dermatology, 56(2): 148-153, https://onlinelibrary.wiley.com/doi/abs/10.1111/ijd.13517
Piana, M., Silva, M.A., Trevisan, G., de Brum, T.F., Silva, C.R., Boligon, A.A., Oliveira, S.M., Zadra, M., Hoffmeister, C., Rossato, M.F., Tonello, R., Laporta, L.V. (2013) Antiinflammatory effects of Viola tricolor gel in a model of sunburn in rats and the gel stability study. Journal of Ethnopharmacology, 150(2): 458-465, https://www.sciencedirect.com/science/article/pii/S0378874113005941?via%3Dihub
Price, A., Rai, S., Mcleod, R.W.J., Birchall, J.C., Elhassan, H.A. (2018) Topical propranolol for infantile haemangiomas: A systematic review. Journal of the European Academy of Dermatology and Venereology, 32(12): 2083-2089, https://onlinelibrary.wiley.com/doi/abs/10.1111/jdv.14963
Sato, K., Matsumoto, D., Iizuka, F., Aiba-Kojima, E., Watanabe-Ono, A., Suga, H., Inoue, K., Gonda, K., Yoshimura, K. (2006) Anti-androgenic therapy using oral spironolactone for Acne vulgaris in Asians. Aesthetic Plastic Surgery, 30(6): 689-694, https://link.springer.com/article/10.1007%2Fs00266-006-0081-0
Savić, M.M. (2013) Lekovi za dermatološku primenu - klasifikacija i mehanizmi dejstva. Arhiv za farmaciju, vol. 63, br. 2, str. 116-128
Stein-Gold, L., Kircik, L.H., Draelos, Z.D., Werschler, P., Dubois, J., Lain, E., Baumann, L., Goldberg, D.J., Kaufman, J., Tanghetti, E.A., Alvandi, N., Weng, E., Berk, D.R., Ahluwalia, G. (In press) Efficacy and safety of topical oxymetazoline cream 1.0% for treatment of persistent facial erythema associated with rosacea: Findings from the 2 phase 3, 29-day, randomized, controlled REVEAL trials. Journal of the American Academy of Dermatology
Sugarman, J.H., Fleischer, A.B., Feldman, S.R. (2002) Off-label prescribing in the treatment of dermatologic disease. Journal of the American Academy of Dermatology, 47(2): 217-223, https://www.sciencedirect.com/science/article/pii/S0190962202000506?via%3Dihub
Tan, C.E.S., Itinteang, T., Leadbitter, P., Marsh, R., Tan, S.T. (2014) Low-dose propranolol regimen for infantile haemangioma. Journal of Paediatrics and Child Health, 51: 419-24, https://onlinelibrary.wiley.com/doi/abs/10.1111/jpc.12720
Tanghetti, E., Dover, J., Goldberg, D.J., et al. (2018) Topical oxymetazoline hydrochloride 1.0% effectively reduces persistent facial erythema of rosacea on day 1. Journal of the American Academy of Dermatology, 79 (3), Supplement 1: AB299, https://www.jaad.org/issue/S0190-9622(18)X0002-4
The Congress of the United States, Congressional Budget Office (2006) Research and development in the pharmaceutical industry. October, https://www.cbo.gov/sites/default/files/109thcongress-2005-2006/reports/10-02-drugr-d.pdf
Wang, Y., Zhang, X., Yang, Y., Zhang, J., Yang, Y., Lu, Y. (2017) Efficacy and safety of 2% topical propranolol cream for the treatment of proliferating infantile strawberry hemangiomas. Indian Journal of Pediatrics, 84(6): 425-429, https://link.springer.com/article/10.1007/s12098-017-2303-7
Xu, G., Lv, R., Zhao, Z., Huo, R. (2012) Topical propranolol for treatment of superficial infantile hemangiomas. Journal of the American Academy of Dermatology, 67(6): 1210-1213, https://www.sciencedirect.com/science/article/pii/S0190962212003507?via%3Dihub
Yamamoto, A., Ito, M. (1996) Topical spironolactone reduces sebum secretion rates in young adults. Journal of Dermatology, 23(4): 243-246, https://onlinelibrary.wiley.com/doi/abs/10.1111/j.1346-8138.1996.tb04006.x
 

O članku

jezik rada: engleski
vrsta rada: pregledni članak
DOI: 10.5937/afmnai37-25282
objavljen u SCIndeksu: 06.08.2020.
metod recenzije: dvostruko anoniman
Creative Commons License 4.0

Povezani članci

Arhiv za farmaciju (2013)
Lekovi za dermatološku primenu - klasifikacija i mehanizmi dejstva
Savić Miroslav M.

Arhiv za farmaciju (2005)
Nega kože dece u prvoj godini života
Pavlović Miloš D.